Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031957 | 1.00 | SLC6A4 (0.64) | SLC6A4DPP4DPP7MEN1KMT2A | |
| SCHEMBL288206 | 1.00 | SLC6A4 (0.64) | SLC6A4DPP4DPP7MEN1KMT2A | |
| SCHEMBL288276 | 0.83 | SLC7A5 (0.61) | ANPEPENPEPSLC6A2 | |
| SCHEMBL28064621 | 0.83 | ANPEP (0.51) | SLC6A4DPP4ANPEPENPEP | |
| SCHEMBL27999577 | 0.83 | ANPEP (0.51) | SLC6A4DPP4ANPEPENPEP | |
| SCHEMBL25229867 | 0.83 | SLC7A5 (0.61) | ANPEPENPEPSLC6A2 | |
| SCHEMBL28064620 | 0.83 | ANPEP (0.51) | SLC6A4DPP4ANPEPENPEP | |
| SCHEMBL28064695 | 0.83 | ANPEP (0.51) | SLC6A4DPP4ANPEPENPEP | |
| SCHEMBL288929 | 0.83 | ANPEP (0.51) | SLC6A4DPP4ANPEPENPEP | |
| SCHEMBL123055 | 0.82 | EPHX1 (0.64) | DPP4ANPEPENPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SLC6A4 1543/4885DPP4 1357/4885DPP7 865/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | SLC6A4 3287/4885DPP4 1217/4885DPP7 481/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SLC6A4 308/4885DPP4 1271/4885DPP7 1768/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | SLC6A4 3838/4885DPP4 1374/4885DPP7 453/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | SLC6A4 2056/4885DPP4 2835/4885DPP7 1615/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | SLC6A4 3722/4885DPP4 265/4885DPP7 232/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | SLC6A4 4361/4885DPP4 677/4885DPP7 694/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | SLC6A4 4710/4885DPP4 128/4885DPP7 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.